Texas is currently home to 4891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of AZD0754 in Participants With Metastatic Prostate Cancer
NCT06267729
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
Gender:
MALE
Ages:
Between 18 years and 130 years
Trial Updated:
06/27/2025
Locations: Research Site, Houston, Texas
Conditions: Metastatic Prostate Cancer
Register for Updates
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
NCT06245915
Recruiting
This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence
Register for Updates
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
NCT06163391
Recruiting
This is a Phase 1, open-label, dose escalation study to assess the safety, tolerability, and preliminary efficacy of SOT201 as monotherapy for participants aged 18 years or above with advanced unresectable or metastatic solid tumors During dose escalation, the recommended dose(s) of SOT201 given every 3 weeks (Q3W) will be determined
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
NCT06016088
Recruiting
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/27/2025
Locations: Dell Children's Medical Center of Central Texas, Austin, Texas
Conditions: Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
Register for Updates
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPĪ±-CD47 Pathway, in Solid or Hematological Tumors
NCT05892718
Recruiting
The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma
Register for Updates
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324
Recruiting
To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: University of Texas Md Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
Register for Updates
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
NCT05776225
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Premier Pulmonary Critical Care and Sleep Medicine, Denison, Texas
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates
Reducing Posttraumatic Stress Disorder (PTSD) Symptoms in First Responders and Frontline Health Care Workers
NCT05751473
Recruiting
This study addresses PTSD symptoms in First Responders and Healthcare workers. Specifically, it tests whether a brief PTSD treatment (talk therapy) effectively treats PTSD when provided to First Responders and Healthcare workers by counselors in Employee Assistance Programs (EAPs). The central hypothesis is that the PTSD treatment, Prolonged Exposure for Primary Care (PE-PC), will reduce PTSD symptoms and improve functioning, compared to EAP Treatment as Usual (TAU).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Houston Fire Department, Houston, Texas
Conditions: Post Traumatic Stress Disorder
Register for Updates
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451
Recruiting
The purpose of this trial is: 1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to \< 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by H1-antihistamines 2. to collect long-term efficacy, safety and tolerability data on remibrutinib in adolescents after having completed 24 weeks of treatment 3. to collect safety data in this population for up to three years after the last dose of study treatment
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
06/27/2025
Locations: RFSA Dermatology, San Antonio, Texas
Conditions: Chronic Spontaneous Urticaria
Register for Updates
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/27/2025
Locations: ANESC Research, El Paso, Texas
Conditions: Primary Generalized Tonic-Clonic Seizures
Register for Updates
Life's End Benefits of cannaBidiol and tetrahYdrocannabinol
NCT05644262
Recruiting
This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks. This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation hospice care-eligible patients with agitation and dementia as measured by the Cohen Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks. This study will enroll approximat... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/27/2025
Locations: Baylor Scott & White AT&T Medical Center, Dallas, Texas
Conditions: Agitation, Dementia
Register for Updates
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
NCT05614063
Recruiting
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Austin Epilepsy Care Center (AECC), Austin, Texas
Conditions: Focal Onset Seizures
Register for Updates